Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In
J&J Might Have More To Offer For Coronavirus Than Biotechs
As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.
